This is a minor procedural win for BSX in one of many pelvic mesh cases. It does not change the overall litigation landscape. Monitor for any class action or MDL developments, but this individual case is immaterial to BSX's financials.
Price Chart
Executive Summary
A federal magistrate judge barred the plaintiffs' economic expert in a single product-liability case against Boston Scientific over its Obtryx pelvic mesh sling, due to the plaintiffs' repeated failure over two years to produce tax returns needed for the defense's rebuttal. This is a procedural win for BSX in an individual case, but the ruling does not resolve liability or set precedent for the broader pelvic mesh litigation.
Court Ruling Details
Key Facts
- Court barred plaintiffs' economic expert Andrew Verzilli under Rule 37(c)(1) for failure to produce tax returns despite multiple court orders and extensions over two years.
- The case is an individual product-liability action (not a class action or MDL) involving the Obtryx Transobturator Mid-Urethral Sling System.
- No monetary damages were awarded; the ruling only limits plaintiffs' ability to present expert testimony on lost wages.
- Boston Scientific is a $70B market cap company; this single case is immaterial to its financials.
Financial Impact
No monetary damages awarded; ruling limits plaintiffs' ability to prove lost wages in this individual case.
Risk Factors
- Other pelvic mesh cases against BSX may proceed with expert testimony on economic damages.
- Plaintiffs could appeal the exclusion ruling, though success is unlikely given the extensive record of non-compliance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-85673bd292-BSX |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Court Ruling | $48.30 $43.88 | ▼ −9.15% | ▼ −8.96% | $42.45 (−12.11%) |
Aug 26, 2026 5w ago | 8-K | $48.17 $43.72 | ▲ +9.24% | ▲ +10.44% | $42.45 (+11.87%) |
Aug 22, 2026 5w ago | Institutional Cluster | $49.01 $44.92 | ▼ −8.35% | ▼ −9.66% | $42.45 (−13.39%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $42.45 (−13.91%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $42.45 (−13.91%) |
Aug 5, 2026 8w ago | Insider Cluster | $47.74 $48.37 | ▲ +1.32% | ▲ +1.92% | $42.45 (−11.08%) |
Jul 29, 2026 9w ago | 8-K | $46.04 $48.17 | ▼ −4.63% | ▲ +0.39% | $42.45 (+7.80%) |
Jul 27, 2026 9w ago | 8-K | $46.06 $49.86 | ▲ +8.25% | ▲ +4.87% | $42.45 (−7.84%) |
Jul 27, 2026 9w ago | Court Ruling | $45.51 $49.01 | ▲ +7.69% | ▲ +4.39% | $42.45 (−6.72%) |
Jul 10, 2026 12w ago | Court Ruling | $44.77 $49.30 | ▲ +10.11% | ▲ +7.69% | $42.45 (−5.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access